Bigpharma Dealmaking and Agreements Handbook 2007

Summary

This report combines two reports - BigPharma Dealmaking Handbook and BigPharma Agreements Handbook, the summaries for each can be found below:

BigPharma Dealmaking Handbook

The Bigpharma Dealmaking Handbook 2007 provides an in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company's business development objectives.

The initial chapters of this report provide an orientation of bigpharma's dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2006 pharmaceutical revenues. Chapter 3 analyses the most active dealmakers in 2005 and 2006 in M&A and partnering deals announced, whilst chapter 4 analyzes the top deals of 2005-6 according to reported deal size.

Chapter 5 provides a summary on best practice on how to submit an opportunity to bigpharma, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner. Chapter 6 lists forthcoming partnering events where valuable face to face meetings with bigpharma provide a highly effective means of obtaining interest in novel opportunities.

The main body of the report is provided in chapter 7 and 8. Firstly, a series of matrices provide a cross reference for each bigpharma company versus therapy area with respect to marketed and pipeline activity, partnering interests, and partnering activity in the last two years. Secondly, in-depth profiles of every bigpharma company provide everything required to assess the suitability of a company as a prospective partner. This includes a company overview, detailed analysis of the company's marketed and pipeline disease targets, partnering interests, partnering activity according to deal type, phase of development, therapy area. Each profile also includes in-depth contact information for individuals within the business development function.

In addition, each company profile provides a listing of deal contract documents available in the public domain, each of which can be obtained from CurrentPartnering, either individually or as part of a contract set. See each company profile for further details.

Key benefits

Bigpharma Dealmaking Handbook 2007 provides the user with the following key benefits:

• A comprehensive overview of the partnering activities and interests of the leading fifty biopharma companies
• Identify prospective partner companies by analyzing their dealmaking activity and interests
• Undertake initial due diligence to assess suitability of partner companies
• Make direct contact with over 1,300 named business development executives
• Identify over 1,000 actual contract agreements entered into by the company and its partner companies
• Understand the key deal terms the company has agreed in previous deals

Report scope

Bigpharma Dealmaking Handbook 2007 is intended to provide the reader with an in-depth understanding of the partnering activities and interests of the leading fifty biopharma companies worldwide, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company's approach to partnering.

Bigpharma Dealmaking Handbook 2007 includes:

• The tools to enable effective and efficient partnering with bigpharma
• Detailed partnering activity and interests profiles for the leading fifty bigpharma companies
• Direct contact information for over 1,300 bigpharma dealmakers
• Listing of over 1,000 contract documents between bigpharma and partner companies
• The leading M&A and partnering deals by value 2005-6
• Most active M&A and partnering dealmakers 2005-6
• Guidelines on how to submit partnering opportunities to bigpharma
• The leading partnering resources and networking events

The Bigpharma Dealmaking Handbook 2007 provides a comprehensive profile for each of the fifty bigpharma companies, including:

• Detailed company profile
• In-depth marketed and pipeline activity of each company
• Partnering interests statement and therapy focus
• Partnering activity for 2005-2006
• Activity by deal type
• Activity by phase of development
• Activity by therapeutic area
• List of recent partner companies
• Direct contact information for dealmakers
• General company and partnering contact information
• List of contract documents available* to allow analysis of bigpharma deal terms

BigPharma Agreements Handbook

The Bigpharma Agreements Handbook 2007 provides comprehensive and unprecedented access to the partnering agreements entered into by the worlds leading fifty biopharma companies.

Understanding the flexibility of a prospective partner's negiotated deals terms provides critical insight into the negotiation process in termsof what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains over 1,000 links to online copies of actual contract documents as submitted to the Securities Exchange Commission by bigpharma and their partners.

Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each parties ability to derive value from the deal.

The initial chapters of this report provide an orientation of bigpharma's dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2006 pharmaceutical revenues. Chapter 3 analyses the most active dealmakers in 2005 and 2006 in M&A and partnering deals announced, whilst chapter 4 analyzes the top deals of 2005-6 according to reported deal size.

The main body of the report is provided in chapter 5. Each of the top 50 bigpharma companies is provided with a brief summary followed by a comprehensive listing of contract documents available in the public domain. The listing is sorted by deal type - therefore co-promotion deals are listed separately to licensing, M&A and supply deals, and so on.

Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. In addition, the contract document collection can be used offline and is available on CD-Rom.

Key benefits

Bigpharma Agreements Handbook 2007 provides the user with the following key benefits:

• Comprehensive access to over 1,000 actual contracts entered into by the leading fifty biopharma companies*
• Insight into the terms included in a partnering agreement, together with real world clause examples
• Understand the key deal terms the company has agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Bigpharma Agreements Handbook 2007 is intended to provide the reader with an in-depth understanding of the partnering activities and interests of the leading fifty biopharma companies worldwide, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company's approach to partnering.

Bigpharma Agreements Handbook 2007 includes:

• The tools to enable effective and efficient preparation for partnering negotiation with bigpharma
• Detailed partnering activity and interests profiles for the leading fifty bigpharma companies
• Listing of over 1,000 contract documents between bigpharma and partner companies
• The leading M&A and partnering deals by value 2005-6
• Most active M&A and partnering dealmakers 2005-6
• The leading partnering resources

For each company in Bigpharma Agreements Handbook 2007, the available contracts are listed by deal type, including:

• Co-development
• Co-marketing
• Co-promotion
• Collaborative R&D
• Development
• Distribution
• Joint venture
• Licensing
• M&A
• Manufacturing
• Marketing
• Promotion
• Research
• Supply

Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand. In addition, the contract document collection can be used offline and is available on CD-Rom.

The Bigpharma Agreements Handbook 2007 provides comprehensive access to available contract documents for each of the fifty bigpharma companies. Analyzing actual company agreements allows assessment of the following:

• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subscontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Contents

BigPharma Dealmaking Handbook

• Executive Summary
• Chapter 1 - Introduction
• Chapter 2 - Bigpharma - The Top 50
• Chapter 3 - Most active bigpharma dealmakers
  • 3.1 Bigpharma M&A activity
  • 3.2 Bigpharma partnering
• Chapter 4 - Top bigpharma deals - 2000-6
  • 4.1 Bigpharma M&A
  • 4.2 Bigpharma partnering
• Chapter 5 - Submitting Opportunities to Bigpharma
  • 5.1 How to submit an opportunity
  • 5.2 Opportunity submission template
  • 5.3 Sending emails
  • 5.4 Face to face at partnering events
  • 5.5 Online submission forms
• Chapter 6 - Forthcoming bigpharma partnering events
  • 6.1 Forthcoming events
• Chapter 7 - Bigpharma company - therapy locator
  • 7.1 How to use the therapy matrix tables
  • 7.2 Therapeutic area definitions
  • 7.3 Bigpharma - Therapeutic target matrix - marketed and pipeline compounds
  • 7.5 Bigpharma - Therapeutic target matrix - expressed partnering interests
  • 7.6 Bigpharma - Therapeutic target matrix - recent deals - 2005-2006
• Chapter 8 - Bigpharma Company Profiles
  • 8.1 How to use company profiles
  • 8.2 Field definitions
  • 8.3 Company profiles
• Each profile includes:
  • Company contact details
  • Subsidiary companies
  • Primary therapy areas
  • Business development contacts
  • Company description
  • Marketed therapeutic indications
  • Pipeline (phase I-III) therapeutic indications
  • Partnering interests
  • Partnering interests - therapeutic indications
  • Partnering frequency per annum - 2000-2006
  • Current partner companies (2005-6)
  • Recent deals 2005-2006
  • By deal type
  • By stage of development
  • By therapy area
  • Contract documents available
  • Company profiles:
  • Abbott
  • Actavis
  • Akzo Nobel
  • Allergan
  • Altana
  • Amgen
  • Astellas
  • AstraZeneca
  • Baxter International
  • Bayer
  • Bayer Schering Pharma AG
  • Biogen Idec
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Cephalon
  • Chugai
  • CSL
  • Dainippon Sumitomo
  • Eisai
  • Eli Lilly
  • Forest Laboratories
  • Genentech
  • Genzyme
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • King
  • Lundbeck
  • Menarini
  • Merck & Co
  • Merck - Serono KGaA
  • Mitsubishi
  • Novartis AG
  • Novo Nordisk
  • Nycomed Pharma
  • Otsuka
  • Pfizer
  • Procter & Gamble
  • Roche
  • Sanofi-Aventis
  • Schering Plough
  • Serono
  • Shionogi Seiyaku
  • Shire
  • Solvay
  • Takeda
  • Tanabe Seiyaku
  • TAP Pharmaceuticals
  • Teva
  • UCB
  • Watson
  • Wyeth
• Chapter 9 - Resources
  • Appendices
• Appendix 1 - Example contract document
  • About CurrentPartnering
  • Recent titles from CurrentPartnering
  • Order form - Reports
  • Order form - Company Dealmaking Profiles
  • Order Form - Company Contract Sets
  • Order Form - contract sets
  • Order Form - contract documents
  • Order Form - Report update subscription
• Figures in report
  • Figure 1: Bigpharma - top 50 by pharma revenues 2006
  • Figure 2: Additional bigpharma companies profiled in report
  • Figure 3: Leading Bigpharma M&A companies, 2005-6
  • Figure 4: Leading Bigpharma partnering companies, 2005-6
  • Figure 5: Leading M&A deals by value, 2005-6
  • Figure 6: Leading partnering deals by value, 2005-6
  • Figure 7: Typical partnering opportunity submission template
  • Figure 8: Partnering events 2007-8
  • Figure 9: Therapeutic area definitions
  • Figure 10: Therapeutic target matrix - marketed and pipeline compounds
  • Figure 11: Therapeutic target matrix - expressed partnering interests
  • Figure 12: Therapeutic target matrix - recent deals 2005-6
  • Figure 13: Company profile template and definitions used in report
  • Figure 14: Online partnering resources
  • Figure 15: Development and license agreement between Boehringer Ingelheim and Inspire Pharmaceuticals, February 2006

BigPharma Agreements Handbook

• Executive Summary
• Chapter 1 - Introduction
• Chapter 2 - Bigpharma - The Top 50
• Chapter 3 - Most active bigpharma dealmakers
  • 3.1 Bigpharma M&A activity
  • 3.2 Bigpharma partnering
• Chapter 4 - Top bigpharma deals - 2000-6
  • 4.1 Bigpharma M&A
  • 4.2 Bigpharma partnering
• Chapter 5 - Bigpharma Agreements
  • 5.1 How to use bigpharma agreements
  • 5.2 What should an agreement contain?
  • 5.3 Deal type definitions
  • 5.4 Company agreement listings
    • Abbott
    • Actavis
    • Akzo Nobel
    • Allergan
    • Altana
    • Amgen
    • Astellas
    • AstraZeneca
    • Baxter International
    • Bayer
    • Bayer Schering Pharma AG
    • Biogen Idec
    • Boehringer Ingelheim
    • Bristol-Myers Squibb
    • Cephalon
    • Chugai
    • CSL
    • Dainippon Sumitomo
    • Eisai
    • Eli Lilly
    • Forest Laboratories
    • Genentech
    • Genzyme
    • Gilead Sciences
    • GlaxoSmithKline
    • Johnson & Johnson
    • King
    • Lundbeck
    • Menarini
    • Merck & Co
    • Merck - Serono KGaA
    • Mitsubishi
    • Novartis AG
    • Novo Nordisk
    • Nycomed Pharma
    • Otsuka
    • Pfizer
    • Procter & Gamble
    • Roche
    • Sanofi-Aventis
    • Schering Plough
    • Serono
    • Shionogi Seiyaku
    • Shire
    • Solvay
    • Takeda
    • Tanabe Seiyaku
    • TAP Pharmaceuticals
    • Teva
    • UCB
    • Watson
    • Wyeth
• Chapter 6 - Resources
  • Appendices
• Appendix 1 - Example development and license contract document
• Appendix 2 - Example M&A contract document
  • About CurrentPartnering
  • Recent report titles from CurrentPartnering
  • Order Form - Reports
  • Order Form - Report Update Subscription
  • Order form - Company Dealmaking Profiles
  • Order Form - CD-Rom
• Figures in report
  • Figure 1: Bigpharma - top 50 by pharma revenues 2006
  • Figure 2: Additional bigpharma companies profiled in report
  • Figure 3: Leading Bigpharma M&A companies, 2005-6
  • Figure 4: Leading Bigpharma partnering companies, 2005-6
  • Figure 5: Leading M&A deals by value, 2005-6
  • Figure 6: Leading partnering deals by value, 2005-6
  • Figure 7: Checklist of key contract agreement clauses in a partnering agreement
  • Figure 8: Deal type definitions
  • Figure 9: Online partnering resources
  • Figure 10: Development and license agreement between Boehringer Ingelheim and Inspire Pharmaceuticals, February 2006
  • Figure 11: Agreement and plan of merger between Johnson & Johnson and Guidant Corporation